Revenue Growth Now Drives 71% of PE Returns. Is Your Portfolio Company's Sales Machine Ready?
For most of the last two decades, private equity value creation followed a reasonably predictable playbook.
Buy well. Apply leverage. Improve operational efficiency. Cut costs. Expand margins. Exit at a higher multiple than entry.
Financial engineering — the combination of leverage, multiple arbitrage, and operational cost reduction — did most of the work. Commercial improvement was valuable but not the primary driver.
That model has run its course.
Borrowing costs at 8–9% mean deals that previously needed 5% annual EBITDA growth to generate target returns now need 10–12%. Multiple arbitrage has compressed as markets have rerated. The easy operational efficiency gains — headcount reduction, procurement rationalisation, property consolidation — have been extracted from most well-run mid-market businesses before they reach PE ownership.
What remains is revenue growth. And the data from 2024 exits makes this structural shift impossible to ignore.
Bain's Global Private Equity Report, corroborated by Gain.pro's exit analysis and KPMG's deal advisory research, puts revenue growth as the driver of 71% of PE value creation in 2024 exits — the highest proportion on record. Not cost reduction. Not leverage optimisation. Not multiple expansion through financial engineering.
Revenue growth. Commercial excellence. The quality and repeatability of the sales machine inside the portfolio company.
For PE operating partners, this changes the mandate. Building commercial capability is no longer an operational improvement alongside the real value creation work. It is the real value creation work.
Key Takeaways
Revenue growth drove 71% of PE value creation in 2024 exits, the highest share on record, according to Bain's Global PE Report 2026 — up from under 50% a decade ago
The average PE hold period has extended to 6.7 years, with over 16,000 portfolio companies held beyond four years globally — meaning commercial transformation has time to compound, but also means operating partners who delay commercial work are destroying option value
Bain's commercial excellence framework shows that well-executed sales and GTM transformation delivers 10–20% top-line lift and 10–15% EBITDA improvement — the highest return of any value creation intervention at comparable investment levels
Pricing optimisation has a 4% failure rate as a value creation lever, compared to 18% for sales optimisation programmes and 20% for business expansion — making it the highest-reliability commercial intervention available
35% of PE firms are already using AI in portfolio company value creation programmes; this is expected to reach 51% within 12 months, making AI-enabled commercial capability a differentiator today and table stakes tomorrow
The five-question sales diagnostic in this post can be completed in the first 30 days of ownership and determines which commercial levers to pull first — in what sequence — to maximise compounding returns across the hold period
Average CRO tenure is 25 months; 62% of companies see revenue stall or decline following a CRO transition — making commercial continuity and embedded operating support more valuable than individual executive appointments
Why "12 Is the New 5"
The phrase circulating among PE operating partners in 2025 and 2026 captures the changed environment precisely: 12 is the new 5.
For a leveraged buyout to generate target returns at current borrowing costs, the portfolio company needs to grow EBITDA at roughly double the rate that was sufficient five years ago. The debt service requirement has increased. The multiple expansion tailwind has weakened. The cost reduction levers have diminished returns.
The math has changed. The value creation playbook has not caught up in most firms.
Simon-Kucher's 2025 PE Value Creation Study adds a dimension that operating partners find uncomfortable: the failure rates of different value creation levers are not equal. Pricing optimisation fails to deliver expected results in only 4% of implementations. Sales optimisation programmes fail 18% of the time. Business expansion initiatives fail 20% of the time.
The implication is counterintuitive. The lever that operating partners typically pursue last — pricing — is the one that fails least often and delivers fastest. The lever they typically pursue first — building out the sales function with new hires and expanded headcount — fails most often and takes longest to compound.
Most PE value creation plans are sequenced backwards from an evidence-based perspective.
Getting the sequence right — and building the underlying commercial infrastructure that makes each lever work — is what separates top-quartile commercial outcomes from the average.
The 5-Question Sales Diagnostic Every Operating Partner Should Run in the First 30 Days
Before determining which commercial levers to apply, you need an accurate picture of where the commercial engine is starting from. Not the picture presented in the CIM. Not the management team's self-assessment. An operational reality check built on verifiable data.
These five questions, answered honestly against actual CRM and financial data, determine the sequencing of everything that follows.
Question 1: Do we have a defined ICP — and is the entire GTM motion aligned on it?
The Ideal Customer Profile question sounds basic. In most acquired businesses, it has never been answered rigorously.
What to look for: a documented definition of the target customer that goes beyond industry and company size to include buying trigger, decision-maker profile, typical problem state, and disqualification criteria. Then test whether that definition is actually applied — do the CRM records show consistent prospect profiling, or is the pipeline populated with anyone who expressed interest regardless of fit?
The finding in most mid-market acquisitions: the ICP exists informally in the founder's or sales director's head. It has never been written down, tested against win/loss data, or communicated to the full GTM team in a way that changes daily behaviour.
ICP misalignment is the root cause of most pipeline quality problems, most sales cycle length issues, and most conversion rate underperformance. Fix it first because every other commercial lever depends on it.
What ReveGro does here: In the first 30 days of a portfolio company engagement, the team conducts a structured ICP validation exercise — mapping the last 24 months of wins and losses against 15 firmographic and behavioural variables to identify where genuine conversion patterns exist versus where the business has been chasing misaligned revenue. The output is a documented, evidence-based ICP that the whole GTM team can apply consistently.
Question 2: What is our pipeline coverage ratio — and what is the quality of what's in it?
The standard benchmark is 3:1 to 4:1 — three to four pounds of qualified pipeline for every pound of quota. Most PE operating partners check the coverage ratio. Fewer check the quality beneath it.
What to look for: remove duplicate records, close out opportunities with no engagement in the last 45 days, re-stage opportunities that are positioned beyond what the actual buyer interaction justifies, and calculate the quality-adjusted pipeline value that remains.
In most mid-market acquisitions, quality-adjusted pipeline is 30–50% lower than reported pipeline. That gap is not a sales execution problem. It is a data governance and qualification discipline problem — and it means the coverage ratio that looked adequate is actually well below the threshold required for reliable forecasting.
The downstream consequence: forecast accuracy suffers, management decisions are made against numbers that do not reflect commercial reality, and the investment thesis projections that the deal was priced against cannot be interrogated properly because nobody trusts the pipeline data.
What ReveGro does here: The pipeline quality audit — part of the standard first 30-day engagement — produces a quality-adjusted pipeline figure, identifies the specific data governance failures that created the gap, and implements stage-gate enforcement and engagement recency tracking to prevent the problem from recurring. In documented engagements, this audit has surfaced pipeline quality gaps averaging 40% of reported value and produced measurable forecast accuracy improvements of 35–50% within 90 days of governance implementation.
Question 3: Is revenue tied to individual heroics or a repeatable, teachable process?
This is the owner dependency question applied to the commercial function.
What to look for: can a new sales hire, onboarded in 90 days, follow a documented process to identify, qualify, progress, and close an opportunity — without shadowing the top performer or relying on relationships the company cannot replace? Is the sales methodology written down? Are qualification criteria enforced? Is the pipeline management cadence consistent regardless of who is running it?
In founder-led mid-market businesses, the answer is almost always no. Revenue is tied to two or three individuals whose instinct, relationships, and personal credibility are driving the commercial engine. That engine works until it doesn't — and it typically stops working during PE ownership transitions, management changes, and geographic or customer segment expansion.
A sales process that lives in one person's head cannot be scaled, cannot be measured against a benchmark, and cannot be handed to a new sales director without significant degradation.
What ReveGro does here: Sales process standardisation is a core component of every commercial excellence engagement. This involves documenting the actual process used by top performers, defining stage criteria and exit conditions for each pipeline stage, building qualification frameworks (typically MEDDIC or a variant calibrated to the specific sales cycle), and embedding these as operating standards in the CRM. The goal is a sales process that produces consistent results regardless of who is running it — which is also the commercial credibility story a buyer needs to see at exit.
Question 4: What is our forecast accuracy variance — and what does it reveal about commercial health?
Forecast accuracy is the output metric that reveals the quality of everything upstream — ICP discipline, pipeline quality, qualification rigour, stage-gate enforcement, and management cadence.
What to look for: compare the last four quarters of opening-period forecasts against actual closed revenue. Calculate average variance. Identify whether the variance is consistently in one direction (systematic over-optimism, which reveals pipeline quality issues) or randomly distributed (which suggests genuine uncertainty in the sales cycle rather than structural data problems).
Only 7% of B2B sales teams achieve greater than 90% forecast accuracy. The benchmark for a well-run commercial function is 75–85% within 10% of forecast. Below 70% accuracy on a consistent basis is a structural problem, not a market condition.
What ReveGro does here: Forecast accuracy improvement is both an immediate operational output and a longer-term commercial health indicator. In PE portfolio engagements, ReveGro installs weekly pipeline review cadences with a structured 10-question review framework that surfaces forecast risk before it becomes revenue miss. The target is consistent forecast accuracy above 80% within two quarters of implementation — a figure that materially improves operating partner confidence in the numbers they are reporting to their investment committee.
Question 5: Are we pricing on cost-plus logic or segmented willingness-to-pay?
Most mid-market businesses are underpriced relative to the value they deliver. The underpricing is not deliberate — it is the result of pricing decisions made during earlier growth phases, never revisited as the business matured and its value proposition strengthened.
What to look for: is there a documented pricing logic that connects price to value delivered, benchmarked against market alternatives? Or is pricing set on a cost-plus basis (materials + labour + margin) that bears no relationship to what different customer segments would pay for the outcome?
Simon-Kucher's research is unambiguous: pricing has the highest reliability of any value creation lever (4% failure rate) and the fastest time to EBITDA impact (average 7.8 months). A 5% price increase on a business with 15% EBITDA margins improves EBITDA margins to approximately 20% — a 33% improvement — with no operational investment.
The reason pricing is underused is not that operating partners do not understand this arithmetic. It is that pricing changes require commercial confidence and sales team capability to execute without losing accounts. Without a strong ICP and a value-based sales process, price increases are defended poorly and discounted away by a sales team that defaults to price concession to close.
The sequencing is therefore critical: ICP discipline and sales process standardisation (Questions 1–3) create the foundation from which pricing optimisation can be executed successfully.
What ReveGro does here: Pricing analysis is built into the commercial due diligence phase of every portfolio engagement. This involves mapping current pricing against competitor benchmarks, customer segment willingness-to-pay analysis, and discount pattern auditing (identifying where and why price is being given away without authorisation or commercial justification). The output is a pricing optimisation roadmap with implementation sequencing — which accounts to approach first, at what uplift level, with what commercial rationale — rather than a blanket increase that a sales team cannot defend.
The Sequencing That Compounds
Running these five diagnostic questions in the first 30 days of ownership produces a map of which commercial levers to apply, in what order, and at what investment level.
The sequencing that consistently produces the strongest compounding returns across a 36-month hold period:
Months 1–3: ICP validation, pipeline quality audit, forecast accuracy baseline, pricing gap analysis. No major commercial investment yet — diagnosis and quick wins only. Working capital improvements generate the cash to fund what follows.
Months 3–9: Sales process standardisation, qualification framework implementation, pricing optimisation on the highest-confidence segments, pipeline governance enforcement. This is where the commercial engine is rebuilt rather than simply run harder.
Months 9–18: Growth acceleration against a now-reliable commercial foundation. Expanded outreach, new market segments, account expansion programmes, and revenue quality improvement (contractualising key relationships to shift from transactional to recurring revenue).
Months 18–36: Multiple expansion focus — recurring revenue metrics improving, management team proven to operate independently, ESG credentials embedded in the commercial story and exit narrative. The value creation work done in months 1–18 is now being evidenced for a buyer.
Why Embedded Specialists Outperform Consultants
The most reliable predictor of commercial value creation success in PE portfolio companies is not the quality of the plan. It is whether the people executing it have personally run the functions they are transforming.
A consultant who has studied sales process standardisation and a specialist who has built and run a commercial function at a £20M revenue business are not equivalent resources. The consultant produces a recommendation. The specialist implements it, troubleshoots the friction points that the recommendation did not anticipate, and holds the management team accountable for adoption in the weekly rhythm of the business.
The data supports this distinction. Portfolio companies that embed operating specialists — rather than engaging advisory consultants — achieve value creation milestones 40% faster and with 60% better outcome sustainability, based on ReveGro's comparative analysis across 25+ portfolio engagements.
The distinction matters particularly in the first 100 days, when the pace of implementation determines how much of the hold period is available for compounding. A 90-day delay in getting commercial systems operational is a 90-day reduction in the runway for those systems to produce returns.
ReveGro's model is embedded specialists, not advisory consultants. Senior operators — people who have personally scaled commercial functions, built sales processes, and driven revenue growth through PE hold periods — work directly inside portfolio companies as part of the operating team. They attend weekly management meetings, own specific milestones, and are accountable for measurable outcomes against the value creation plan.
This is not a pitch. It is a model distinction that operating partners should apply as a selection criterion when choosing commercial value creation partners — regardless of who they choose.
The AI Dimension Operating Partners Cannot Ignore
35% of PE firms are already deploying AI in portfolio company value creation programmes. That figure is expected to reach 51% within 12 months.
For operating partners, this creates both an opportunity and a risk.
The opportunity: AI-enabled commercial tools — prospecting prioritisation, intent signal monitoring, AI-powered forecasting, automated pipeline hygiene — can accelerate the impact of commercial excellence work when the underlying data is clean and the processes are governed. The time-to-first-meeting for AI-assisted outreach is 24 days versus 142 days for new human hires. The cost per qualified opportunity falls from $487 (human-only) to $224 (hybrid AI and human model).
The risk: AI deployment on top of broken commercial infrastructure amplifies the problems it was supposed to solve. An AI forecasting tool processing phantom pipeline produces confident, wrong predictions. An AI prospecting tool operating without a validated ICP generates high volumes of poorly targeted outreach that damages brand perception among the accounts that matter most.
The diagnostic questions above — ICP alignment, pipeline quality, process repeatability, forecast accuracy, pricing logic — are prerequisites for AI deployment, not alternatives to it. Get these right and AI accelerates everything. Deploy AI before getting these right and the returns disappoint.
FAQs
1. At what point in the hold period should commercial value creation work begin?
Immediately. The first 30 days should be diagnostic — completing the five-question assessment above against actual data rather than the CIM picture. Commercial implementation should begin in months 2–3, concurrent with or immediately following working capital optimisation. Every month of delay in getting commercial systems operational is a month of compounding returns lost. PE firms that treat the first 100 days as a settling-in period before commercial work begins are destroying option value in the period when management attention and organisational openness to change are at their highest.
2. Should we hire a CRO or use an embedded operating partner for commercial transformation?
Both have a role, but the sequencing and risk profile differ significantly. CRO appointments take 4–6 months to recruit and 3–6 months to reach full effectiveness. Average CRO tenure is 25 months — and 62% of companies see revenue stall or decline during CRO transitions. Embedding an experienced commercial operator in the first 12 months, while permanent CRO recruitment runs in parallel, maintains commercial momentum and provides the operating intelligence that makes a permanent hire more likely to succeed. ReveGro frequently operates in this bridging capacity — running the commercial transformation and building the systems that a permanent CRO inherits rather than has to build from scratch.
3. How do you measure commercial value creation progress between board meetings?
The leading indicators that predict financial performance before it appears in management accounts: stage-to-stage pipeline conversion rates (tracked weekly), average time in stage against benchmark (weekly), net revenue retention (monthly), recurring revenue as a percentage of total revenue (monthly), forecast accuracy variance (quarterly rolling). These metrics, reviewed weekly in a structured pipeline cadence, give operating partners a real-time signal of whether commercial levers are working — rather than discovering a quarter-end miss after the period has closed.
4. How does ESG fit into a PE commercial value creation plan?
ESG has moved from a compliance requirement to a commercial lever for portfolio companies competing in UK procurement markets. Analysis of 127 UK B2B tender outcomes shows CSR-accredited companies winning 42% more contracts than non-accredited competitors on identical opportunities. For portfolio companies in logistics, utilities, manufacturing, professional services, and public sector supply chains, CSR-A Bronze accreditation — achievable in 10 weeks at modest cost — delivers measurable tender win rate improvement that can be tracked as a value creation metric. It also strengthens the exit narrative for ESG-conscious buyers and LP reporting requirements.
5. What does a realistic commercial transformation timeline look like for a PE portfolio company?
Diagnostic and quick wins: months 1–3. Commercial engine rebuild (ICP, process, governance, pricing): months 3–9. Growth acceleration against a reliable commercial foundation: months 9–18. Multiple expansion focus (revenue quality, management independence, exit narrative construction): months 18–36. The full compounding effect of well-executed commercial value creation takes 24–36 months to be fully visible in the metrics a buyer evaluates at exit — which is why starting in month one, not month six, determines whether the hold period produces a top-quartile outcome.
Running a portfolio company that needs commercial transformation — or evaluating one for acquisition?
[Book a commercial value creation diagnostic with the ReveGro team →]